T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023’, provides an overview of the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
- The report reviews pipeline therapeutics for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) therapeutics and enlists all their major and minor projects
- The report assesses T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AbbVie IncAdienne Pharma & Biotech SA
Affiliated Hospital of Xuzhou Medical University
Allterum Therapeutics LLC
Alpha Biopharma Inc
Arch Oncology Inc
Ascentawits Pharmaceuticals Ltd
AVM Biotechnology LLC
Ayala Pharmaceuticals Inc.
Bambino Gesu Hospital and Research Institute
Baylor College of Medicine
Beam Therapeutics Inc
Beijing Boren Hospital
Bioceltech Therapeutics Ltd
Cellestia Biotech AG
Changzhou Qianhong Bio-Pharma Co Ltd
Chengdu Zenitar Biomedical Technology Co Ltd
Enzyme by Design Inc
Gracell Biotechnologies Inc
Great Ormond Street Hospital for Children NHS Trust
Guangzhou Bio-gene Technology Co Ltd
Hebei Senlang Biotechnology Co Ltd
Houston Methodist Research Institute
iCell Gene Therapeutics LLC
Ichnos Sciences Inc
InnoCure Therapeutics Inc
Integra Therapeutics SL
Jazz Pharmaceuticals Plc
Johnson & Johnson
March Biosciences
MediSix Therapeutics Pte Ltd
MedPacto Inc
Mito BioPharm LLC
Nanjing Bioheng Biotech Co Ltd
National University of Singapore
OBI Pharma Inc
OneChain Immunotherapeutics
Oslo University Hospital
PersonGen BioTherapeutics (Suzhou) Co Ltd
PharmaEssentia Corp
Puretech Health Plc
Sareum Holdings Plc
SciTech Development LLC
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Pregene Biopharma Co Ltd
Shenzhen University General Hospital
Sorrento Therapeutics Inc
St. Jude Children’s Research Hospital Inc
SunRock Biopharma SL
Suzhou Fundamenta Therapeutics Co Ltd
Takeda Pharmaceutical Co Ltd
Vincerx Pharma Inc
Wugen Inc
Xencor Inc
Xuanwu Hospital Capital Medical University
Zentalis Pharmaceuticals Inc
Zhejiang University